NA
FBIO icon

NewEdge Advisors’s Fortress Biotech FBIO Stock Holding History

NewEdge Advisors’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.7K Buy
14,927
+2,000
+15% +$5.16K ﹤0.01% 3142
2026
Q1 		$36.1K Sell
12,927
-19,604
-60% -$66.6K ﹤0.01% 3027
2025
Q4 		$119K Buy
32,531
+20,131
+162% +$57.4K ﹤0.01% 2716
2025
Q3 		$45.8K Buy
12,400
+1,200
+11% +$3.03K ﹤0.01% 2854
2025
Q2 		$20.8K Buy
+11,200
New +$19.4K ﹤0.01% 2948

Other funds holding FBIO

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

NewEdge Advisors's FBIO Position: Q2 2026 in Review

NewEdge Advisors increased its Fortress Biotech (FBIO) stake by 15% in Q2 2026, buying an estimated $5.16K and bringing the position to 14,927 shares worth $45.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3142.

NewEdge Advisors first reported a position in FBIO in Q2 2025 and has held it in 5 quarters since. The position peaked at $119K in Q4 2025. 55 funds tracked by Wall St. Rank hold FBIO as of Q2 2026.

  • NewEdge Advisors held 14,927 shares of Fortress Biotech worth $45.7K as of Q2 2026.
  • NewEdge Advisors bought 2,000 Fortress Biotech shares in Q2 2026, an estimated $5.16K.
  • Fortress Biotech made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3142 holding.
  • NewEdge Advisors first reported a position in Fortress Biotech in Q2 2025 and has held it in 5 quarters since.
  • NewEdge Advisors's Fortress Biotech position peaked at $119K in Q4 2025.
  • 55 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.